VYD 2311
Alternative Names: VYD-2311Latest Information Update: 19 Jun 2024
At a glance
- Originator Invivyd
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 14 Jun 2024 Pharmacodynamics data from the preclinical studies in COVID-2019 infections released by Invivyd
- 31 May 2024 Invivyd announces general alignment with the US FDA for emergency use authorization (EUAs) pathway for VYD 2311 COVID-2019 infections
- 31 May 2024 Invivyd plans registrational clinical trial for COVID-2019 infections (IV)